PathoQ IHC AntibodiesAll PathoQ Products

Medical professionals use pathological diagnosis to assess the morphology, metabolic state, and other aspects of cell and tissue under microscopic analysis. Immunohistochemistry (IHC) remains a crucial diagnostic tool for pathologists to examine biomarkers and determine the extent of disease states from patient samples. ABclonal’s PathoQ® IHC antibodies are designed for optimized use in pathological diagnosis and covers a variety of research interests including oncology, cardiovascular disease, and neurodegenerative disorders.

The ABclonal Advantage

  • Highly-specific and highly-sensitive recombinant monoclonal antibody reagents to improve batch consistency

  • Comprehensively validated on pathological samples

  • Superior positive detection rate ( > 85%)

Versatility in Clinical Diagnostics Using IHC

All PathoQ Products

Determination of the benign or malignant tumors:

the reactive lymphoid hyperplasia or neoplastic hyperplasia can be determined by the light chain of immunoglobulin (Ig) antibody to distinguish the monoclonal/polyclonal of B lymphocyte proliferation.

Determining tumor stage:

Tumor stage is an indicator of prognosis, and is closely related to whether there is invasion. Immunohistochemistry can determine whether the tumor is angiogenesis and lymphangiogenesis or metastasis.

Determination of the cell properties:

The corresponding antigen components in cells are marked by specific antibodies to determine the cell properties and the source of the tumor.

Determining the primary site of metastases from unknown origin:

For metastases from unknown origin, IHC can help determine the histological pattern of the malignant tumor and further find the primary site. For example, keratin antibody (CK20) is usually tested positive in gastrointestinal cancer, bile duct cancer, and pancreatic cancer, but negative in lung cancer, breast cancer, and kidney cancer.

Classification of "undifferentiated" malignant tumors:

Undifferentiated malignant tumors include carcinomas or sarcomas, which cannot be classified due to the lack of origin characteristics of tumor cells on hematoxylin-eosin-stained sections. Non-specific antibodies are used to preliminarily distinguish the histological types, and then specific antibodies are used for further identification based on the results.

Further classification of tumors at different organ-tissue junctions:

In some tissue-organ junction tumors, it is difficult to classify tumors based on histological alone due to the overlapping, such as testicular embryonal carcinoma and seminoma cell carcinoma. It is difficult to distinguish, and the treatment and prognosis are significantly different, but it is easier to distinguish keratin by immunohistochemistry: if the keratin is negative, it is sperm primary cell carcinoma, and while keratin is positive, it is embryonal carcinoma.

Timely and accurate detection of micrometastases:

In regular tissue sections, it is hard to identify micrometastatic tumor cells, and sometimes it is difficult to distinguish sinus histiocytosis in lymph nodes at the early metastasis stage of certain cancers. The IHC method can be used for the timely and accurate detection of micrometastases.

Case Study

PD-L1/CD274 Rabbit mAb (A20344)

Immunohistochemistry of human intestinal gland tissue using PD-L1 mAb (negative control, 40x lens).

Immunohistochemistry of paraffin-embedded Human lung adenocarcinoma using PD-L1/CD274/CD274 Rabbit mAb (A20344) at dilution of 1:200 (40x lens)

Immunohistochemistry of paraffin-embedded Human lung cancer sarcoma using PD-L1/CD274/CD274 Rabbit mAb (A20344) at dilution of 1:200 (40x lens).

Cytokeratin 19 (KRT19) Rabbit mAb (A19040)

Immunohistochemistry of paraffin-embedded human breast cancer using Cytokeratin 19 (KRT19) Rabbit mAb (A19040) at dilution of 1:25 (40x lens).

Immunohistochemistry of paraffin-embedded human colon carcinoma using Cytokeratin 19 (KRT19) Rabbit mAb (A19040) at dilution of 1:25 (40x lens).

Immunohistochemistry of paraffin-embedded human placenta using Cytokeratin 19 (KRT19) Rabbit mAb (A19040) at dilution of 1:25 (40x lens).

Androgen Receptor Rabbit mAb (A19611)

Immunohistochemistry of paraffin-embedded Human colon (negative control sample) using Androgen Receptor Rabbit mAb (A19611) at dilution of 1:100 (40x lens).

Immunohistochemistry of paraffin-embedded Human benign prostatic hyperplasia using Androgen Receptor Rabbit mAb (A19611) at dilution of 1:100 (40x lens).

Immunohistochemistry of paraffin-embedded human prostate cancer using Androgen Receptor Rabbit mAb (A19611) at dilution of 1:100 (40x lens).